Ixazomib (Ninlaro®) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with multiple myeloma who have received at least one prior therapy. Ixazomib is a type of medicine called a proteasome inhibitor. It works by blocking proteins that cancer cells need to survive and grow.
Ixazomib, marketed under the brand name Ninlaro, is a prescription medication used in combination with other drugs to treat a specific type of blood cancer. Here's a breakdown of its key aspects:
Function: Proteasome Inhibitor: Ixazomib belongs to a class of drugs called proteasome inhibitors. Proteasomes are cellular structures responsible for breaking down proteins within cells. By inhibiting this process, Ixazomib disrupts the growth and survival of cancer cells.
Applications:
- Multiple Myeloma: Ixazomib is approved for the treatment of adults with multiple myeloma, a cancer of plasma cells in the bone marrow. It's typically used in combination with other chemotherapy drugs as part of a treatment regimen.
Important Considerations:
- Prescription Medication: Requires a doctor's prescription and close monitoring due to potential side effects.
- Combination Therapy: Not used alone but combined with other medications for effective treatment.
- Potential Side Effects: Like any medication, Ixazomib can cause side effects, including:
- Peripheral neuropathy (tingling, numbness, or pain in the hands and feet)
- Diarrhea
- Fatigue
- Thrombocytopenia (low blood platelet count).